Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net income	$ 25,377	$ 224,754
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense	7,024	8,775
Amortization of patents	39,185	38,825
Common stock and options issued for compensation, consulting and vendor services	188,603	383,720
Accrued interest expense on notes payable		48,639
Bad debt reversal		(239,501)
Loss on Medical Joint Venture	343,716	47,093
Loss on Education Venture	7,822
Changes in operating assets and liabilities:
Decrease in accounts receivable	89,470	276,549
(Increase) in inventories	(642,738)	(218,559)
Decrease to advances on contracts	634,670	155,070
Decrease to prepaid expenses and other current assets	16,491	115,406
Decrease in accounts payable	(986,396)	(830,805)
Increase in customer advances	209,000
Increase (Decrease) in accrued expenses	239,404	(1,727)
Net cash provided by operating activities	171,628	8,239
Cash flows from investing activities:
Investment in Medical Joint Venture	(180,351)	(47,093)
Investment in Education Joint Venture		(50,000)
Investment in Treasury Bills	(9,498,498)
Purchases of property and equipment	(21,189)	(2,790)
Payments for patent rights		(16,565)
Net cash used in investing activities	(9,700,038)	(116,448)
Cash flows from financing activities:
Proceeds from exercise of stock options	103,250	29,600
Proceeds from the sale of common stock		50,000
Net proceeds on Private Placement Offering in May 2014	9,449,683
Proceeds from related party loan		50,000
Repayment from related party loan	(50,000)	(15,000)
Net cash provided by financing activities	9,502,933	114,600
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(25,477)	6,391
Cash and cash equivalents at beginning of period	1,147,198	165,249
Cash and cash equivalents at end of period	1,121,721	171,640
Supplemental disclosure of non cash investing and financing activities:
Shares issued to directors for the exercise of stock options	41,250	29,600
Shares issued to directors for compensation	55,200	45,000
Shares issued to employees for exercise of stock options	24,000
Shares issued to employees in lieu of cash compensation	23,750	23,750
Shares issued to consultants for exercise of stock options	38,000
Net proceeds on Private Placement Offering	$ 9,449,683